Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment

被引：19

作者：

Barragan, Patricia ^{[1
]}

Podzamczer, Daniel ^{[1
]}

机构：

[1] Hosp Univ Bellvitge, Barcelona 08907, Spain

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2008年 / 9卷 / 13期

关键词：

HIV-1; treatment; lopinavir/ritonavir; protease inhibitor;

D O I：

10.1517/14656566.9.13.2363

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: Lopinavir is a protease inhibitor with high specificity for HIV-1 protease formulated with ritonavir. Numerous clinical trials have shown that lopinavir/ritonavir (LPV/r) is highly effective as a component of highly active antiretroviral therapy (HAART) regimens for HIV-1 infection. Objective: In this article we provide an overview of the properties of LPV/r and the experience with its use in HIV-infected adults and adolescents. Methods: We reviewed the literature and selected the most important published articles on LPV/r and the latest posters/communications presented in conferences, with particular attention to the clinical efficacy and tolerability of LPV/r in HIV-1 infected patients. Conclusion: LPV/r is highly effective as a component of HAART regimens for HIV-1 infection. There is considerable experience with the drug in both treatment-naive and treatment-experienced patients. In general, LPV/r is well tolerated and its high genetic barrier to resistance favours long-term efficacy.

引用

页码：2363 / 2375

页数：13

共 79 条

[1]

*ABB LAB, 2001, KAL EUR SUMM PROD CH

[2] Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors [J].

Acosta, EP ;

Kakuda, TN ;

Brundage, RC ;

Anderson, PL ;

Fletcher, CV .

CLINICAL INFECTIOUS DISEASES, 2000, 30 :S151-S159

[3]

[Anonymous], 1982, Morbidity and Mortality Weekly Report, V31, P507

[4]

ARRIBAS J, 2007, 14 C RETR OPP INF 25

[5]

ARRIBAS J, 2007, 11 EUR AIDS C 24 27

[6] Lopinavir/ritonavir as single-drug therapy for maintenance of HlV-1 viral suppression -: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK study) [J].

Arribas, JR ;

Pulido, F ;

Delgado, R ;

Lorenzo, A ;

Miralles, P ;

Arranz, A ;

González-García, JJ ;

Cepeda, C ;

Hervás, R ;

Paño, JR ;

Gaya, F ;

Carcas, A ;

Montes, ML ;

Costa, JR ;

Peña, JM .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 40 (03) :280-287

[7]

*ARTEMIS, 2007, 47 INT C ANT AG CHEM

[8]

Awni W, 2005, 3 IAS C HIV PATH TRE

[9] Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients [J].

Benson, CA ;

Deeks, SG ;

Brun, SC ;

Gulick, RM ;

Eron, JJ ;

Kessler, HA ;

Murphy, RL ;

Hicks, C ;

King, M ;

Wheeler, D ;

Feinberg, J ;

Stryker, R ;

Sax, PE ;

Riddler, S ;

Thompson, M ;

Real, K ;

Hsu, A ;

Kempf, D ;

Japour, AJ ;

Sun, E .

JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (05) :599-607

[10]

Bertz R, 2004, 11 C RETR OPP INF 8

← 1 2 3 4 5 6 7 8 →